The Project of the Consortium, composed of the Novasome Research and Development Centre and the Pikralidacompany, has been selected by the National Centre for Research and Development to receive funding under 1/1.1.1/2021 Szybka Ścieżka (‘Fast Track’) competition. The total cost of the Project was set at PLN 9.6 million, and the recommended funding amount is PLN 5.8 million.
The aim of Project POIR.01.01.01-00-0072-21 is to develop a technology innovation and to verify the latter in real conditions using a pilot kilo-lab line that enables efficient and safe synthesis of active pharmaceutical ingredients (APIs). The Project will involve the design of a process system to allow for a variety of synthesis processes as well as the on-line monitoring of how individual reactions proceed. Once implemented, the innovation will contribute to the integrity of supply chains and availability of APIs, and therefore to ensuring pharmaceutical sovereignty in the EU.
- Project budget: 9,582,401.43 PLN
- EU funding for the project: 5,765,803.30 PLN
- Duration of the Project: 01 Jul 2021 – 31 Dec 2023
The implementation of the project in a consortium of a large entity and an SME will be a unique example of bilateral knowledge transfer, while allowing for streamlining competencies and resources of both research teams. The developed output will constitute important know-how to form the basis for further advanced research projects, and the talks on the latter are already underway – says Tomasz Han, CEO of Novasome sp. z o.o. z o.o.
We are excited to work with the Novasome Team on designing and validating an innovative process system based on the API model synthesis pathway developed by our process chemistry team. The prospective system will allow for various biologically active substances to be produced on a semi-technical scale in the future. It is good to know that the expertise and experience of our team in the scope of development of synthesis processes will contribute to gaining new competencies by our Business Partner. We believe that the implementation of this project will let us contribute to ensuring the pharmaceutical sovereignty in the European Union, as well as strengthening the potential of the Polish pharmaceutical industry – says Stanisław Pikul, President of Pikralida sp. z o.o.
The output of the Project will meet the needs of the national and EU pharmaceutical sector, while being in line with the current Pharmaceutical Strategy for Europe, including increasing the capacity to produce medicines and APIs across the EU in order to bolster the resilience of healthcare systems in view of emergency situations. The implementation of the Project will allow to secure the availability of drugs in the list of the Ministry of Health which are currently at risk of not being available in Poland.
Further information about the project is available from:
CBR Novasome:
Maciej Barys
e-mail: m.barys@cbr.novasome.pl
Martyna Jasik
e-mail: m.jasik@cbr.novasome.pl
Pikralida:
Joanna Lipner
e-mail: j.lipner@pikralida.eu
Wrocław & Poznań, 30 lipca 2021 r.
